ArticleNature communications2023
Comprehensive analysis reveals potential therapeutic targets and an integrated risk stratification model for solitary fibrous tumors.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 22 citations in OpenAlex.
- Carbon-Ion Radiation Therapy for Unresectable Solitary Fibrous Tumor of the Intermediate Category: A Nationwide Multi-institutional Observational Study by the Japan Carbon-Ion Radiation Oncology Study Group.Advances in radiation oncology · 2026Article
- Systemic Therapy for Solitary Fibrous Tumor.Current treatment options in oncology · 2026Review
- Real-World Surgical Experience with Thoracic Solitary Fibrous Tumors: Outcomes from a High-Volume Indian Center.Indian journal of surgical oncology · 2026Article
- Primary orbital solitary fibrous tumor with an 18-year course of five recurrences and extensive sinonasal metastasis following eyeball enucleation: a case report.Frontiers in medicine · 2026Article
- Clinical and hematological indices as prognosticators in localized solitary fibrous tumors: A retrospective study.Therapeutic advances in medical oncology · 2026Article
- Solitary Fibrous Tumors of the Pleura With Extensive Intrathoracic Occupation: Report of Two Cases.Case reports in pulmonology · 2026Article
- Comparison of automated and manual approaches for microglial quantification and classification: A focus on the HALO digital pathology platform.Brain pathology (Zurich, Switzerland) · 2026Article
- Robot-assisted laparoscopic resection of giant pelvic solitary fibrous tumor: a case report with literature review.Frontiers in oncology · 2026Article
- Soft Tissue Masses of the Hand.Seminars in musculoskeletal radiology · 2025Review
- Molecular landscape, subtypes, and therapeutic vulnerabilities of central nervous system solitary fibrous tumors.Nature communications · 2025Article
- A schwannoma look-alike: solitary fibrous tumor of the cauda equina. Illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Solitary fibrous tumors from A to Z: a pictorial review with radiologic-pathologic correlation.Insights into imaging · 2025Article
- Exploring the role of immune checkpoint inhibitors in solitary fibrous tumors.Immunotherapy · 2025Article
- Meningeal solitary fibrous tumor cell states phenocopy cerebral vascular development and homeostasis.Neuro-oncology · 2025Article
- Primary solitary fibrous tumor of the liver: an uncommon neoplasm.Gastroenterology report · 2025Article
- Solitary fibrous tumour: histological discoveries, behavioural aspects, risk assessment and therapeutical approaches.Therapeutic advances in medical oncology · 2025Review
- Advances in the molecular biology of the solitary fibrous tumor and potential impact on clinical applications.Cancer metastasis reviews · 2024Review
- Article
- Systemic metastasis in malignant solitary fibrous tumor of the liver: two case reports and literature review.Frontiers in oncology · 2024Article
- Cystic intracranial solitary fibrous tumor: a case report.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Solitary fibrous tumors (SFTs) are rare mesenchymal tumors with unpredictable evolution and with a recurrence or metastasis rate of 10-40%. Current medical treatments for relapsed SFTs remain ineffective. Here, we identify potential therapeutic targets and risk factors, including IDH1 p.R132S, high PD-L1 expression, and predominant macrophage infiltration, suggesting the potential benefits of combinational immune therapy and targeted therapy for SFTs. An integrated risk model incorporating mitotic count, density of Ki-67+ cells and CD163+ cells, MTOR mutation is developed, applying a discovery cohort of 101 primary non-CNS patients with negative tumor margins (NTM) and validated in three independent cohorts of 210 SFTs with the same criteria, and in 36 primary CNS SFTs with NTM. Compared with the existing models, our model shows significantly improved efficacy in identifying high-risk primary non-CNS and CNS SFTs with NTM for tumor progression.Our findings hold promise for advancing therapeutic strategies and refining risk prediction in SFTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.